The Indian Journal of Chest Diseases and Allied Sciences

Register      Login

VOLUME 65 , ISSUE 3 ( July-September, 2023 ) > List of Articles


Refractory Autoimmune Pulmonary Alveolar Proteinosis Treated with Inhalational GM-CSF: A Case Report

Sandeep Nayar, Imaad Rahman, Sunny Kalra, Manish Garg, Shreshth Nayar

Keywords : Case report, GM-CSF, Ground glass opacities, Pulmonary alveolar proteinosis

Citation Information : Nayar S, Rahman I, Kalra S, Garg M, Nayar S. Refractory Autoimmune Pulmonary Alveolar Proteinosis Treated with Inhalational GM-CSF: A Case Report. Indian J Chest Dis Allied Sci 2023; 65 (3):160-162.

DOI: 10.5005/jp-journals-11007-0092

License: CC BY-NC 4.0

Published Online: 05-02-2024

Copyright Statement:  Copyright © 2023; The Author(s).


Aim and background: Pulmonary alveolar proteinosis is a rare entity with definite evidence to show symptomatic improvement with whole lung lavage therapy. Refractory autoimmune pulmonary alveolar proteinosis continues to be a mystery as upcoming treatment modalities still show variable results. Case description: We hereby present a case of a 40-year-old female who presented with acute severe shortness of breath with a cough for 3–4 days and was a transbronchial biopsy-proven case of pulmonary alveolar proteinosis. On admission to intensive care unit (ICU), the patient was started on inhalational granulocyte–macrophage colony-stimulating factor (GM-CSF). Conclusion: Starting a patient on inhalational GM-CSF provided significant clinical improvement with a decrease in dependence on long-term oxygen therapy thus showing the value of this possible treatment in managing refractory autoimmune pulmonary alveolar proteinosis. Clinical significance: This case highlights the importance of inhalational GM-CSF therapy as a treatment modality for refractory autoimmune pulmonary alveolar proteinosis.

  1. Yu Hy, Sun Xf, Wang Yx, et al. Whole lung lavage combined with Granulocyte-macrophage colony stimulating factor inhalation for an adult case of refractory pulmonary alveolar proteinosis. BMC Pulm Med 2014;14:87. DOI: 10.1186/1471-2466-14-87.
  2. Khan A, Agarwal R. Pulmonary alveolar proteinosis. Respir Care 2011;56(7):1016–1028. DOI: 10.4187/respcare.01125.
  3. Suzuki T, Trapnell BC. Pulmonary alveolar proteinosis syndrome. Clin Chest Med 2016;37(3):431–440. DOI: 10.1016/j.ccm.2016.04.006.
  4. Keske A, Destrampe EM, Barksdale B, et al. Pulmonary alveolar proteinosis refractory to plasmapheresis and rituximab despite GM-CSF antibody reduction. Case Rep Immunol 2022;2022:2104270. DOI: 10.1155/2022/2104270.
  5. Sheng G, Chen P, Wei Y, et al. Better approach for autoimmune pulmonary alveolar proteinosis treatment: Inhaled or subcutaneous granulocyte-macrophage colony-stimulating factor: A meta-analyses. Respir Res 2018;19(1):163. DOI: 10.1186/s12931-018- 0862-4.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.